Syngene announces expansion of biomanufacturing capacity

Bengaluru: Syngene International, an integrated research, development and cGMP manufacturing services company, has announced the expansion of its biomanufacturing capacity.

The Company has set up and commissioned a new microbial cGMP facility and has also expanded the capacity of its mammalian cell manufacturing facility to extend end-to-end Chemistry, Manufacturing and Control (CMC) development solutions for its global clients.

Both facilities are located at its Biocon Park campus in Bengaluru, India. The new microbial facility has two fermenters of 200 Litres and 500 Litres capacity. The microbial facility will provide further integration opportunities with the Company's existing Discovery and Development capabilities and extend service offerings in the space of GMP manufacturing of plasmid DNA and mRNA.

In addition to this, another 2000L single use bioreactor will be added to the USFDA and EMA compliant mammalian manufacturing facility. This is expected to strengthen Syngene's service offerings for commercial supply. The expansion is building on Syngene's existing biopharmaceuticals manufacturing capabilities and is aligned with its strategic focus on biologics as one of its future growth drivers.